Lantern Pharma (LTRN) Investor Presentation - Slideshow

NASDAQ: LTRN LP-300 has additional MoA's that can give it chemo-protective and chemo-sensitization properties • Reduce glutathione/thioredoxin mediated tumor resistance to therapy • Nephrotoxicity protection against chemotherapy LP-300 binding to ALK inactivates it in a dose dependent manner LP-184 has Blockbuster Potential Across Multiple Cancers as a Single Agent or in Combination Therapy DDR Deficient Tumors Including: Phase 1 trial in 2023* *Anticipated Timeline • Low nanomolar anti-cancer potency, heal ...